XML 16 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Business Activities (Details)
1 Months Ended 3 Months Ended 9 Months Ended 11 Months Ended
Oct. 01, 2019
Sep. 30, 2019
product
patient
Dec. 06, 2018
shares
Nov. 01, 2018
shares
Feb. 08, 2018
USD ($)
milestone_payment
Nov. 16, 2016
USD ($)
milestone_payment
shares
Dec. 06, 2018
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
product
patient
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
product
patient
shares
Oct. 30, 2018
USD ($)
Subsidiary, Sale of Stock [Line Items]                        
Number of products | product   2             2   2  
Shares of common stock repurchased (in shares) | shares                     2,855,316  
Value of common stock repurchased               $ 12,109,000 $ 15,000,000 $ 22,628,000 $ 168,900,000  
Eagle Biologics                        
Subsidiary, Sale of Stock [Line Items]                        
Payments to acquire business           $ 27,209,000            
Business combination equity consideration (in shares) | shares           40,200            
Business combination equity consideration           $ 3,046,000            
Number of milestone payments | milestone_payment           4            
Milestone Payments | Eagle Biologics                        
Subsidiary, Sale of Stock [Line Items]                        
Business combination, contingent consideration range of outcome high         $ 48,000,000 $ 48,000,000            
Business combination consideration including contingent consideration           $ 78,000,000            
Number of milestone payments | milestone_payment         4              
Contingent consideration lump sum milestone payment         $ 15,000,000              
Teva Pharmaceuticals                        
Subsidiary, Sale of Stock [Line Items]                        
Proceeds from upfront payment                 $ 9,000,000      
Cephalon, Inc.                        
Subsidiary, Sale of Stock [Line Items]                        
Royalty revenue, percentage of net sales (in percentage)   25.00%                    
October 2018 Plan                        
Subsidiary, Sale of Stock [Line Items]                        
Stock repurchase program, authorized amount                       $ 150,000,000
Accelerated share repurchase                        
Subsidiary, Sale of Stock [Line Items]                        
Stock repurchase program, authorized amount                       50,000,000
Shares of common stock repurchased (in shares) | shares     297,146 702,988     1,000,134   2,855,316      
Additional shares                        
Subsidiary, Sale of Stock [Line Items]                        
Stock repurchase program, authorized amount                       $ 100,000,000
Scenario | Cephalon, Inc.                        
Subsidiary, Sale of Stock [Line Items]                        
Maximum royalty revenue percentage (in percentage) 32.00%                      
Scenario | Cephalon, Inc. | Maximum                        
Subsidiary, Sale of Stock [Line Items]                        
Annual increase to royalty revenue percentage 1.00%                      
Ryanodex                        
Subsidiary, Sale of Stock [Line Items]                        
Number of patients | patient   41             41   41  
Subsequent event | Cephalon, Inc.                        
Subsidiary, Sale of Stock [Line Items]                        
Royalty revenue, percentage of net sales (in percentage) 30.00%